# Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial

> **NCT05382741** · PHASE2 · UNKNOWN · sponsor: **Ospedale Policlinico San Martino** · enrollment: 182 (estimated)

## Conditions studied

- Colorectal Cancer Stage IV
- No Evidence of Disease State

## Interventions

- **DRUG:** Durvalumab Injection for intravenous use 500 mg vial solution for infusion
- **DRUG:** Regorafenib 30 mg capsules

## Key facts

- **NCT ID:** NCT05382741
- **Lead sponsor:** Ospedale Policlinico San Martino
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-02
- **Primary completion:** 2024-03-02
- **Final completion:** 2024-03-02
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2023-05-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05382741

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05382741, "Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05382741. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*